No records
|
516 |
Rosa B.A., Snowden C., Martin J., Fischer K., Kupritz J., Beshah E., Supali T., Gankpala L., Fischer P.U., Urban J.F., Jr., Mitreva M. |
15519661800;57215576664;56537265100;55807725800;57211116674;6506448106;6602742029;55801653400;23567680200;7202366458;6507392205; |
Whipworm-Associated Intestinal Microbiome Members Consistent Across Both Human and Mouse Hosts |
2021 |
Frontiers in Cellular and Infection Microbiology |
11 |
|
637570 |
|
|
|
3 |
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85103118895&doi=10.3389%2ffcimb.2021.637570&partnerID=40&md5=27cf0d3a842448c6a8e6d26ccd8dd43e |
Division of Infectious Diseases, Department of Medicine, Washington University School of Medicine, St. Louis, MO, United States; U.S. Department of Agriculture, Agricultural Research Service, Beltsville Agricultural Research Center, Animal Parasitic Diseases Laboratory, Beltsville, MD, United States; Department of Parasitology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Public Health and Medical Research, National Public Health Institute of Liberia, Charlesville, Liberia; Department of Genetics, Washington University School of Medicine, St. Louis, MO, United States; McDonnell Genome Institute, Washington University in St. Louis, St. Louis, MO, United States |
Rosa, B.A., Division of Infectious Diseases, Department of Medicine, Washington University School of Medicine, St. Louis, MO, United States; Snowden, C., Division of Infectious Diseases, Department of Medicine, Washington University School of Medicine, St. Louis, MO, United States; Martin, J., Division of Infectious Diseases, Department of Medicine, Washington University School of Medicine, St. Louis, MO, United States; Fischer, K., Division of Infectious Diseases, Department of Medicine, Washington University School of Medicine, St. Louis, MO, United States; Kupritz, J., Division of Infectious Diseases, Department of Medicine, Washington University School of Medicine, St. Louis, MO, United States; Beshah, E., U.S. Department of Agriculture, Agricultural Research Service, Beltsville Agricultural Research Center, Animal Parasitic Diseases Laboratory, Beltsville, MD, United States; Supali, T., Department of Parasitology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Gankpala, L., Public Health and Medical Research, National Public Health Institute of Liberia, Charlesville, Liberia; Fischer, P.U., Division of Infectious Diseases, Department of Medicine, Washington University School of Medicine, St. Louis, MO, United States; Urban, J.F., Jr., U.S. Department of Agriculture, Agricultural Research Service, Beltsville Agricultural Research Center, Animal Parasitic Diseases Laboratory, Beltsville, MD, United States; Mitreva, M., Division of Infectious Diseases, Department of Medicine, Washington University School of Medicine, St. Louis, MO, United States, Department of Genetics, Washington University School of Medicine, St. Louis, MO, United States, McDonnell Genome Institute, Washington University in St. Louis, St. Louis, MO, United States |
The human whipworm Trichuris trichiura infects 289 million people worldwide, resulting in substantial morbidity. Whipworm infections are difficult to treat due to low cure rates and high reinfection rates. Interactions between whipworm and its host’s intestinal microbiome present a potential novel target for infection control or prevention but are very complicated and are identified using inconsistent methodology and sample types across the literature, limiting their potential usefulness. Here, we used a combined 16S rRNA gene OTU analysis approach (QIIME2) for samples from humans and mice infected with whipworm (T. trichiura and T. muris, respectively) to identify for the first time, bacterial taxa that were consistently associated with whipworm infection spanning host species and infection status using four independent comparisons (baseline infected vs uninfected and before vs after deworming for both humans and mice). Using these four comparisons, we identified significant positive associations for seven taxa including Escherichia, which has been identified to induce whipworm egg hatching, and Bacteroides, which has previously been identified as a major component of the whipworm internal microbiome. We additionally identified significant negative associations for five taxa including four members of the order Clostridiales, two from the family Lachnospiraceae, including Blautia which was previously identified as positively associated with whipworm in independent human and mouse studies. Using this approach, bacterial taxa of interest for future association and mechanistic studies were identified, and several were validated by RT-qPCR. We demonstrate the applicability of a mouse animal model for comparison to human whipworm infections with respect to whipworm-induced intestinal microbiome disruption and subsequent restoration following deworming. Overall, the novel cross-species analysis approach utilized here provides a valuable research tool for studies of the interaction between whipworm infection and the host intestinal microbiome. © Copyright © 2021 Rosa, Snowden, Martin, Fischer, Kupritz, Beshah, Supali, Gankpala, Fischer, Urban and Mitreva. |
animal model; helminth; intestinal microbiota; microbiome; whipworm |
albendazole; ivermectin; mebendazole; RNA 16S; RNA 16S; adult; ancylostomiasis; Article; Bacteroides; Blautia; child; Clostridiales; DNA extraction; Escherichia; feces analysis; female; gene sequence; human; infection control; intestine flora; Lachnospiraceae; male; molecular genetics; morbidity; nonhuman; polymerase chain reaction; real time polymerase chain reaction; reverse transcription polymerase chain reaction; taxonomy; trichuriasis; Trichuris muris; Trichuris trichiura; animal; genetics; microflora; mouse; trichuriasis; Trichuris; Animals; Gastrointestinal Microbiome; Humans; Mice; Microbiota; RNA, Ribosomal, 16S; Trichuriasis; Trichuris |
Frontiers Media S.A. |
22352988 |
|
33777847 |
Article |
Q1 |
1812 |
1607 |
|
|
517 |
Anindyajati G., Wiguna T., Murtani B.J., Christian H., Wigantara N.A., Putra A.A., Hanafi E., Minayati K., Ismail R.I., Kaligis F., Savitri A.I., Uiterwaal C.S.P.M., Diatri H. |
57194606169;24367785700;57216652176;57209266195;57218679014;57220161382;56737010600;57218681686;55996895500;36604651700;56401804100;7006033434;36113389500; |
Anxiety and Its Associated Factors During the Initial Phase of the COVID-19 Pandemic in Indonesia |
2021 |
Frontiers in Psychiatry |
12 |
|
634585 |
|
|
|
2 |
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85102995915&doi=10.3389%2ffpsyt.2021.634585&partnerID=40&md5=b28d0b2bafd0f4413cc6d469ba102a50 |
Department of Psychiatry, Faculty of Medicine, Universitas Indonesia—Cipto Mangunkusumo Hospital, Jakarta, Indonesia; The Center for Clinical Epidemiology and Evidence-Based Medicine Faculty of Medicine, Universitas Indonesia—Cipto Mangunkusumo Hospital, Jakarta, Indonesia; Julius Global Health, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, Netherlands |
Anindyajati, G., Department of Psychiatry, Faculty of Medicine, Universitas Indonesia—Cipto Mangunkusumo Hospital, Jakarta, Indonesia; Wiguna, T., Department of Psychiatry, Faculty of Medicine, Universitas Indonesia—Cipto Mangunkusumo Hospital, Jakarta, Indonesia; Murtani, B.J., Department of Psychiatry, Faculty of Medicine, Universitas Indonesia—Cipto Mangunkusumo Hospital, Jakarta, Indonesia; Christian, H., Department of Psychiatry, Faculty of Medicine, Universitas Indonesia—Cipto Mangunkusumo Hospital, Jakarta, Indonesia; Wigantara, N.A., Department of Psychiatry, Faculty of Medicine, Universitas Indonesia—Cipto Mangunkusumo Hospital, Jakarta, Indonesia; Putra, A.A., Department of Psychiatry, Faculty of Medicine, Universitas Indonesia—Cipto Mangunkusumo Hospital, Jakarta, Indonesia; Hanafi, E., Department of Psychiatry, Faculty of Medicine, Universitas Indonesia—Cipto Mangunkusumo Hospital, Jakarta, Indonesia; Minayati, K., Department of Psychiatry, Faculty of Medicine, Universitas Indonesia—Cipto Mangunkusumo Hospital, Jakarta, Indonesia; Ismail, R.I., Department of Psychiatry, Faculty of Medicine, Universitas Indonesia—Cipto Mangunkusumo Hospital, Jakarta, Indonesia; Kaligis, F., Department of Psychiatry, Faculty of Medicine, Universitas Indonesia—Cipto Mangunkusumo Hospital, Jakarta, Indonesia; Savitri, A.I., The Center for Clinical Epidemiology and Evidence-Based Medicine Faculty of Medicine, Universitas Indonesia—Cipto Mangunkusumo Hospital, Jakarta, Indonesia; Uiterwaal, C.S.P.M., Julius Global Health, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, Netherlands; Diatri, H., Department of Psychiatry, Faculty of Medicine, Universitas Indonesia—Cipto Mangunkusumo Hospital, Jakarta, Indonesia |
Introduction: Coronavirus disease 2019 (COVID-19) is caused by a novel coronavirus which has not been identified previously in humans. The disease leads to respiratory problems, systemic disorders, and death. To stop the virus transmission, physical distancing was strongly implemented, including working and school from home (WFH & SFH). The limitation altered daily routines and needs advanced to adapt. Many have felt uncomfortable and this could have triggered anxiety symptoms. This study aimed to evaluate the proportion of significant anxiety symptoms and its association with COVID-19-related situations in an Indonesian context during the initial months of the pandemic. Methods: An online community survey was distributed through social media and communication platforms, mainly WhatsApp, targeting people >18 years old in Indonesia. Anxiety symptoms were assessed using Generalized Anxiety Disorder-7 (Indonesian Version). Demographical data and information on social situation related to the COVID-19 pandemic were collected. The proportion of clinically significant anxiety symptoms was calculated and the association with demographic and social factors was assessed using chi square test (χ2) and logistic regression for multivariate analysis. Results: Out of 1215 subjects that completed the survey, 20.2% (n = 245) exhibited significant anxiety symptoms. Several factors, such as age (AOR = 0.933 CI 95% = 0.907–0.96), sex (AOR = 1.612 CI 95% = 1.097–2.369), medical workers (AOR = 0.209 CI 95% = 0.061–0.721), suspected case of COVID-19 (AOR = 1.786 CI 95% = 1.001–3.186), satisfaction level of family support (AOR = 3.052 CI 95% = 1.883–4.946), and satisfaction level of co-workers (AOR = 2.523 CI 95% = 1.395–4.562), were associated with anxiety. Conclusion: One out of five Indonesian people could have suffered from anxiety during the COVID-19 pandemic. The riskiest group being young females, people who had suspected cases of COVID-19, and those with less satisfying social support. Nevertheless, health workers were found to have a lesser risk of developing anxiety. Accessible information and healthcare, social connection, supportive environment, and mental health surveillance are important to prevent bigger psychiatric problems post-pandemic. © Copyright © 2021 Anindyajati, Wiguna, Murtani, Christian, Wigantara, Putra, Hanafi, Minayati, Ismail, Kaligis, Savitri, Uiterwaal and Diatri. |
anxiety; COVID-19 pandemic; Indonesian; mental health surveillance; psychosocial support |
adult; anxiety disorder; Article; controlled study; coronavirus disease 2019; disease association; female; generalized anxiety disorder; high risk population; human; Indonesia; major clinical study; male; mental health; pandemic; patient satisfaction; psychosocial care; risk assessment; risk factor; social support; support group |
Frontiers Media S.A. |
16640640 |
|
|
Article |
Q1 |
1363 |
2668 |
|
|
518 |
Apriadi W., Gani H.S., Prayitno P., Ibrahim N., Wijaya S.K. |
57205292872;57202775842;57222538092;56609777400;6506884322; |
Development of multithread acquisition system for high quality EEG signal measurement |
2021 |
Journal of Physics: Conference Series |
1816 |
1 |
012072 |
|
|
|
|
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85103129496&doi=10.1088%2f1742-6596%2f1816%2f1%2f012072&partnerID=40&md5=8df825ddfea9b100797241af3b95358e |
Department of Physics, FMIPA Universitas Indonesia, Depok, 16424, Indonesia; Department of Physiology, Medical Faculty, Universitas Indonesia, Jakarta, 10430, Indonesia |
Apriadi, W., Department of Physics, FMIPA Universitas Indonesia, Depok, 16424, Indonesia; Gani, H.S., Department of Physics, FMIPA Universitas Indonesia, Depok, 16424, Indonesia; Prayitno, P., Department of Physics, FMIPA Universitas Indonesia, Depok, 16424, Indonesia; Ibrahim, N., Department of Physiology, Medical Faculty, Universitas Indonesia, Jakarta, 10430, Indonesia; Wijaya, S.K., Department of Physics, FMIPA Universitas Indonesia, Depok, 16424, Indonesia |
This work was concerned on development of the EEG acquisition and EEG signal processing by adding active electrodes and implementing multithread techniques. By using active electrodes, mounting them on the scalp surface would be easier to capture low signals of less than 1µV. The active electrodes were used to reduce noise when transfer signals from the electrode to the acquisition systems which equipped 20 gain. The verification was performed by comparing the active and passive electrodes using NETECH MiniSIM EEG Simulator 330. The advantage of this research was to reduce time delay for EEG signal computation on 32 channels. The acquisition system was based on Raspberry Pi and ADS1299 with multithread signal treatment. Signal filtering was performed into different threads and put all the EEG features into the database. A PC was used to process signal calculation such as processing FFT, signal feature extractions, and signal analysis. These calculations were divided into several functionally independent computations. The signals of each channel were calculated into different threads. The results of this work showed the effectiveness of the multithreaded method for processing large amounts of data (32 channels of 24 bits EEG signal) with low noise levels on the active electrodes. © Published under licence by IOP Publishing Ltd. |
|
Electrodes; Acquisition systems; Active electrodes; Eeg acquisitions; EEG signal processing; Large amounts of data; Multithread techniques; Signal treatments; Transfer signals; Biomedical signal processing |
IOP Publishing Ltd |
17426588 |
|
|
Conference Paper |
Q4 |
210 |
18731 |
|
|
519 |
Dannatt L., Ransing R., Calvey T., Scheibein F., Saad N.A., Shirasaka T., Ramalho R., Pant S., Vadivel R., Siste K., Stowe M.J., Kalita K.N., Boujraf S., Testa R., Arya S., Morgan N., Grandinetti P. |
57200537348;57190296865;55634512900;57212313904;57219875515;7005625709;56789745200;36114863900;57219874702;55644113100;57217388837;54387032200;57220277366;57222475193;35463222300;57201914207;55487378900; |
The Impact of Stigma on Treatment Services for People With Substance Use Disorders During the COVID-19 Pandemic—Perspectives of NECPAM Members |
2021 |
Frontiers in Psychiatry |
12 |
|
634515 |
|
|
|
5 |
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85102821643&doi=10.3389%2ffpsyt.2021.634515&partnerID=40&md5=f473eb1aa0aba07997e39ee4f82c800a |
Department of Psychiatry and Mental Health, University of Cape Town, Cape Town, South Africa; Department of Psychiatry, Bhaktshreshtha Kamalakarpant Laxman (BKL) Walalwalkar Rural Medical College, Pune, India; Faculty of Health Sciences, School of Anatomical Sciences, University of the Witwatersrand, Johannesburg, South Africa; School of Health Science, Waterford Institute of Technology, Waterford, Ireland; State Drug Dependence Treatment Centre, Ain Shams University, Cairo, Egypt; Department of Psychiatry, Teine Keijinkai Medical Center, Sapporo, Japan; Department of Social and Community Health, School of Population Health, University of Auckland, Auckland, New Zealand; Department of Psychiatry, Institute of Medicine, Tribhuvan University, Kirtipur, Nepal; Department of Psychiatry, Medical Faculty, Universitas Indonesia-Cipto Mangunkusumo Hospital, Jakarta, Indonesia; Department of Family Medicine, Faculty of Health Sciences, School of Medicine, University of Pretoria, Pretoria, South Africa; Department of Psychiatry, Lokopriya Gopinath Bordoloi Regional Institute of Mental Health (LGBRIMH), Tezpur, India; Faculty of Medicine and Pharmacy, Sidi Mohamed Ben Abdellah University, Fez, Morocco; Department of Mental Health, Azienda Sanitaria Locale (ASL), 1 Avezzano-L'Aquila-Sulmona, L'Aquila, Italy; State Drug Dependence Treatment Centre, Institute of Mental Health, Pt. Bhagwat Dayal Sharma (BDS), University of Health Sciences, Rohtak, India; Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa; Department of Mental Helth, Azienda Sanitaria Locale (ASL) Teramo, Teramo, Italy |
Dannatt, L., Department of Psychiatry and Mental Health, University of Cape Town, Cape Town, South Africa; Ransing, R., Department of Psychiatry, Bhaktshreshtha Kamalakarpant Laxman (BKL) Walalwalkar Rural Medical College, Pune, India; Calvey, T., Faculty of Health Sciences, School of Anatomical Sciences, University of the Witwatersrand, Johannesburg, South Africa; Scheibein, F., School of Health Science, Waterford Institute of Technology, Waterford, Ireland; Saad, N.A., State Drug Dependence Treatment Centre, Ain Shams University, Cairo, Egypt; Shirasaka, T., Department of Psychiatry, Teine Keijinkai Medical Center, Sapporo, Japan; Ramalho, R., Department of Social and Community Health, School of Population Health, University of Auckland, Auckland, New Zealand; Pant, S., Department of Psychiatry, Institute of Medicine, Tribhuvan University, Kirtipur, Nepal; Vadivel, R.; Siste, K., Department of Psychiatry, Medical Faculty, Universitas Indonesia-Cipto Mangunkusumo Hospital, Jakarta, Indonesia; Stowe, M.J., Department of Family Medicine, Faculty of Health Sciences, School of Medicine, University of Pretoria, Pretoria, South Africa; Kalita, K.N., Department of Psychiatry, Lokopriya Gopinath Bordoloi Regional Institute of Mental Health (LGBRIMH), Tezpur, India; Boujraf, S., Faculty of Medicine and Pharmacy, Sidi Mohamed Ben Abdellah University, Fez, Morocco; Testa, R., Department of Mental Health, Azienda Sanitaria Locale (ASL), 1 Avezzano-L'Aquila-Sulmona, L'Aquila, Italy; Arya, S., State Drug Dependence Treatment Centre, Institute of Mental Health, Pt. Bhagwat Dayal Sharma (BDS), University of Health Sciences, Rohtak, India; Morgan, N., Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa; Grandinetti, P., Department of Mental Helth, Azienda Sanitaria Locale (ASL) Teramo, Teramo, Italy |
[No abstract available] |
access to treatment; COVID-19; mental health; pandemic; stigma; substance use disorder |
benzodiazepine; naloxone; opiate agonist; Article; behavioral addiction; coronavirus disease 2019; drug dependence; drug dependence treatment; harm reduction; health care access; health care planning; health care policy; high risk population; homelessness; human; mental health care; pandemic; practice guideline; social discrimination; social distancing; stigma; vulnerable population |
Frontiers Media S.A. |
16640640 |
|
|
Article |
Q1 |
1363 |
2668 |
|
|
520 |
Jamtani I., Nugroho A., Rahadiani N., Manangka R.S.W. |
57220165203;57192888914;16426455700;57222276868; |
Challenging retrovesical mass in men: Report of a rare liposarcoma case with concurrent COVID-19 infection |
2021 |
BMJ Case Reports |
14 |
3 |
e241466 |
|
|
|
|
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85102142953&doi=10.1136%2fbcr-2020-241466&partnerID=40&md5=d155998c0d1b2e9350e4a10623455925 |
Department of Surgery, Fatmawati Central General Hospital, Jakarta Selatan, DKI Jakarta, Indonesia; Anatomical Pathology Department, Faculty of Medicine, Universitas Indonesia/Cipto Mangunkusumo National Referral Hostpital, Jakarta, Indonesia; Radiology Department, Mayapada Hospital, DKI Jakarta, Indonesia |
Jamtani, I., Department of Surgery, Fatmawati Central General Hospital, Jakarta Selatan, DKI Jakarta, Indonesia; Nugroho, A., Department of Surgery, Fatmawati Central General Hospital, Jakarta Selatan, DKI Jakarta, Indonesia; Rahadiani, N., Anatomical Pathology Department, Faculty of Medicine, Universitas Indonesia/Cipto Mangunkusumo National Referral Hostpital, Jakarta, Indonesia; Manangka, R.S.W., Radiology Department, Mayapada Hospital, DKI Jakarta, Indonesia |
We describe a case of retrovesical liposarcoma in a male patient with concurrent COVID-19. A 50-year-old man had lower urinary tract symptoms and dull pain along his right gluteus. Due to COVID-19 infection, management was delayed. During self-isolation, the patient developed urinary retention and his pain level was an eight on the Visual Analogue Scale. A urinary catheter and an epidural catheter were inserted without any difficulty. Abdominal-pelvic MRI revealed a retrovesical mass suspected of liposarcoma with clear borders from surrounding organs. Following two consecutive negative SARS-CoV-2 PCR tests, we proceeded with surgery. Histopathology was dedifferentiated liposarcoma. Postoperatively, the patient suffered reactivation of COVID-19, and he was eventually discharged after two consecutive negative results on the PCR test on Post Operative Day (POD)-10. Retrovesical dedifferentiated liposarcoma is rare and considered as high-grade liposarcoma. Although surgery may exacerbate COVID-19 infection, surgical resection of symptomatic high-grade sarcoma is prioritised and performed as soon as no infection detected. © |
cancer intervention; COVID-19; pathology; radiology; surgery |
docetaxel; gemcitabine; adult; Article; bladder catheterization; case report; clinical article; common cold; comorbidity; coronavirus disease 2019; decreased appetite; differential diagnosis; echography; erythrocyte concentrate; fatigue; fever; follow up; histopathology; home quarantine; hospital discharge; human; human tissue; impaired bladder emptying; liposarcoma; lower urinary tract symptom; male; middle aged; multiple cycle treatment; myalgia; neurilemoma; nuclear magnetic resonance imaging; patient history of surgery; physical examination; polymerase chain reaction; positron emission tomography; recurrent disease; retrovesical liposarcoma; retrovesical liposarcoma; surgical approach; urine retention; virus reactivation; visual analog scale; adjuvant chemoradiotherapy; cancer grading; |
BMJ Publishing Group |
1757790X |
|
33653868 |
Article |
Q4 |
231 |
17583 |
|
|
527 |
Supali T., Djuardi Y., Christian M., Iskandar E., Alfian R., Maylasari R., Destani Y., Lomiga A., Minggu D., Lew D., Bogus J., Weil G.J., Fischer P.U. |
6602742029;6507800820;57209806543;57202299885;57222748640;57222744651;57222743128;57205724071;57202307524;57196371851;57170558700;7007028568;23567680200; |
An open label, randomized clinical trial to compare the tolerability and efficacy of ivermectin plus diethylcarbamazine and albendazole vs. Diethylcarbamazine plus albendazole for treatment of brugian filariasis in Indonesia |
2021 |
PLoS Neglected Tropical Diseases |
15 |
3 |
e0009294 |
|
|
|
2 |
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85103946402&doi=10.1371%2fjournal.pntd.0009294&partnerID=40&md5=bf67e831adfbad446acbda06b08e12de |
Department of Parasitology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Universitas Nusa Cendana, Kupang, Lasiana, Kelapa lima, Kota Kupang, Indonesia; Nusa Tenggara Timur Provincial Health Office, Oebobo, Kota Kupang, Nusa Tenggara Timur, Indonesia; Division of Biostatistics, Washington University School of Medicine, St. Louis, MO, United States; Infectious Diseases Division, Department of Medicine, Washington University School of Medicine, St. Louis, MO, United States |
Supali, T., Department of Parasitology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Djuardi, Y., Department of Parasitology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Christian, M., Department of Parasitology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Iskandar, E., Department of Parasitology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Alfian, R., Department of Parasitology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Maylasari, R., Department of Parasitology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Destani, Y., Department of Parasitology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Lomiga, A., Universitas Nusa Cendana, Kupang, Lasiana, Kelapa lima, Kota Kupang, Indonesia; Minggu, D., Nusa Tenggara Timur Provincial Health Office, Oebobo, Kota Kupang, Nusa Tenggara Timur, Indonesia; Lew, D., Division of Biostatistics, Washington University School of Medicine, St. Louis, MO, United States; Bogus, J., Infectious Diseases Division, Department of Medicine, Washington University School of Medicine, St. Louis, MO, United States; Weil, G.J., Infectious Diseases Division, Department of Medicine, Washington University School of Medicine, St. Louis, MO, United States; Fischer, P.U., Infectious Diseases Division, Department of Medicine, Washington University School of Medicine, St. Louis, MO, United States |
Improved treatments for lymphatic filariasis (LF) could accelerate the global elimination program for this disease. A triple drug combination of the anti-filarial drugs ivermectin, diethyl-carbamazine (DEC) and albendazole (IDA) has been shown to be safe and effective for achieving sustained clearance of microfilariae (Mf) of the filarial parasite Wuchereria ban-crofti from human blood. However, the triple drug combination has not been previously been evaluated for treatment of brugian filariasis, which accounts for about 10% of the global LF burden. This hospital-based clinical trial compared the safety and efficacy of IDA with that of the standard treatment (DEC plus albendazole, DA) in persons with Brugia timori infections on Sumba island, Indonesia. Fifty-five asymptomatic persons with B. timori Mf were treated with either a single oral dose of IDA (28 subjects) or with DEC plus albendazole (DA, 27 sub-jects). Participants were actively monitored for adverse events (AE) for two days after treatment by nurses and physicians who were masked regarding treatment assignments. Passive monitoring was performed by clinical teams that visited participant’s home villages for an additional five days. Microfilaremia was assessed by membrane filtration of 1 ml night blood at baseline, at 24h and one year after treatment. IDA was more effective than DA for completely clearing Mf at 24 hours (25/28, 89% vs. 8/27, 30%, P < 0.001). By 12 months after treatment, only one of 27 IDA recipients had Mf in their blood (4%) vs. 10 of 25 (40%) in persons treated with DA (P = 0.002). Approximately 90% of participants had antibodies to recombinant filarial antigen BmR1 at baseline. Antibody prevalence decreased to approximately 30% in both treatment groups at 12 months. About 45% of persons in both treatment groups experienced AE such as fever, muscle aches, lower back, joint and abdominal pain. These were mostly mild and most common during the first two days after treatment. No participant experienced a severe or serious AE. This study showed that IDA was well-tolerated and significantly more effective for clearing B. timori Mf from the blood than DA. Larger studies should be performed to further assess the safety and efficacy of IDA as a mass drug administration regimen to eliminate brugian filariasis. © 2021 Supali et al. |
|
albendazole; antifilarial agent; diethylcarbamazine; immunoglobulin G4; ivermectin; albendazole; antifilarial agent; diethylcarbamazine; ivermectin; protozoon antibody; abdominal pain; adult; antibody titer; arthralgia; Article; body mass; Brugia; Brugian filariasis; Burkholderia pseudomallei; combination drug therapy; controlled study; coughing; daily life activity; double blind procedure; dried blood spot testing; drowsiness; drug efficacy; drug safety; drug tolerability; female; fever; filariasis; follow up; gametocyte; headache; helminthiasis; human; Indonesia; leprosy; low back pain; lymphatic filariasis; major clinical study; male; mass drug administration; microfilariasis; myalgia; pharmacokinetics; Plasmodium falciparum; prevalence; questionnaire; randomized controlled trial; Schis |
Public Library of Science |
19352727 |
|
33780481 |
Article |
Q1 |
1990 |
1322 |
|
|
530 |
Armas Rojas N.B., Lacey B., Simadibrata D.M., Ross S., Varona-Pérez P., Burrett J.A., Calderón Martínez M., Lorenzo-Vázquez E., Bess Constantén S., Thomson B., Sherliker P., Morales Rigau J.M., Carter J., Massa M.S., Hernández López O.J., Islam N., Martínez Morales M.Á., Alonso Alomá I., Achiong Estupiñan F., Díaz González M., Rosquete Muñoz N., Cendra Asencio M., Emberson J., Peto R., Lewington S. |
25122220300;7004338442;57202134322;57222402777;6508209690;18833958600;56323463600;57188694725;57205675816;57194423183;6507011848;35520243600;57203543175;26649987700;57205676718;57217501333;36802068200;57205671350;57205675732;57205677327;57205673279;57205673929;6701688192;34572276000;6601929863; |
Alcohol consumption and cause-specific mortality in Cuba: prospective study of 120 623 adults |
2021 |
EClinicalMedicine |
33 |
|
100692 |
|
|
|
1 |
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85102626908&doi=10.1016%2fj.eclinm.2020.100692&partnerID=40&md5=379be44a40d2f0b3e189516f974772f4 |
National Institute of Cardiology and Cardiovascular Surgery, Havana, Cuba; Nuffield Department of Population Health (NDPH), University of Oxford, United Kingdom; Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Institute of Hygiene, Epidemiology and Microbiology, Ministry of Public Health, Havana, Cuba; Cuban Commission Against Smoking, Ministry of Public Health, Havana, Cuba; Directorate of Medical Records and Health Statistics, Ministry of Public Health, Havana, Cuba; George Institute for Global Health, University of Oxford, United Kingdom; MRC Population Heath Research Unit, NDPH, University of Oxford, United Kingdom; Provincial Center of Hygiene, Epidemiology and Microbiology, Matanzas, Cuba; Municipal Center of Hygiene, Epidemiology and Microbiology, Jagüey Grande, Matanzas, Cuba; Municipal Center of Hygiene, Epidemiology and Microbiology, ColónMatanzas, Cuba; Municipal Center of Hygiene, Epidemiology and Microbiology, Camagüey, Cuba; MRC UKM Medical Molecular Biology Institute (UMBI), NDPH, Malaysia |
Armas Rojas, N.B., National Institute of Cardiology and Cardiovascular Surgery, Havana, Cuba; Lacey, B., Nuffield Department of Population Health (NDPH), University of Oxford, United Kingdom; Simadibrata, D.M., Nuffield Department of Population Health (NDPH), University of Oxford, United Kingdom, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Ross, S., Nuffield Department of Population Health (NDPH), University of Oxford, United Kingdom; Varona-Pérez, P., Institute of Hygiene, Epidemiology and Microbiology, Ministry of Public Health, Havana, Cuba; Burrett, J.A., Nuffield Department of Population Health (NDPH), University of Oxford, United Kingdom; Calderón Martínez, M., Institute of Hygiene, Epidemiology and Microbiology, Ministry of Public Health, Havana, Cuba; Lorenzo-Vázquez, E., Cuban Commission Against Smoking, Ministry of Public Health, Havana, Cuba; Bess Constantén, S., Directorate of Medical Records and Health Statistics, Ministry of Public Health, Havana, Cuba; Thomson, B., Nuffield Department of Population Health (NDPH), University of Oxford, United Kingdom, George Institute for Global Health, University of Oxford, United Kingdom; Sherliker, P., Nuffield Department of Population Health (NDPH), University of Oxford, United Kingdom, MRC Population Heath Research Unit, NDPH, University of Oxford, United Kingdom; Morales Rigau, J.M., Provincial Center of Hygiene, Epidemiology and Microbiology, Matanzas, Cuba; Carter, J., Nuffield Department of Population Health (NDPH), University of Oxford, United Kingdom; Massa, M.S., Nuffield Department of Population Health (NDPH), University of Oxford, United Kingdom; Hernández López, O.J., Municipal Center of Hygiene, Epidemiology and Microbiology, Jagüey Grande, Matanzas, Cuba; Islam, N., Nuffield Department of Population Health (NDPH), University of Oxford, United Kingdom; Martínez Morales, M.Á., Directorate of Medical Records and Health Statistics, Ministry of Public Health, Havana, Cuba; Alonso Alomá, I., Directorate of Medical Records and Health Statistics, Ministry of Public Health, Havana, Cuba; Achiong Estupiñan, F., Provincial Center of Hygiene, Epidemiology and Microbiology, Matanzas, Cuba; Díaz González, M., Municipal Center of Hygiene, Epidemiology and Microbiology, ColónMatanzas, Cuba; Rosquete Muñoz, N., Municipal Center of Hygiene, Epidemiology and Microbiology, Camagüey, Cuba; Cendra Asencio, M., Provincial Center of Hygiene, Epidemiology and Microbiology, Matanzas, Cuba; Emberson, J., Nuffield Department of Population Health (NDPH), University of Oxford, United Kingdom, MRC Population Heath Research Unit, NDPH, University of Oxford, United Kingdom; Peto, R., Nuffield Department of Population Health (NDPH), University of Oxford, United Kingdom; Lewington, S., Nuffield Department of Population Health (NDPH), University of Oxford, United Kingdom, MRC Population Heath Research Unit, NDPH, University of Oxford, United Kingdom, MRC UKM Medical Molecular Biology Institute (UMBI), NDPH, Malaysia |
Background: The associations of cause-specific mortality with alcohol consumption have been studied mainly in higher-income countries. We relate alcohol consumption to mortality in Cuba. Methods: In 1996-2002, 146 556 adults were recruited into a prospective study from the general population in five areas of Cuba. Participants were interviewed, measured and followed up by electronic linkage to national death registries until January 1, 2017. After excluding all with missing data or chronic disease at recruitment, Cox regression (adjusted for age, sex, province, education, and smoking) was used to relate mortality rate ratios (RRs) at ages 35–79 years to alcohol consumption. RRs were corrected for long-term variability in alcohol consumption using repeat measures among 20 593 participants resurveyed in 2006-08. Findings: After exclusions, there were 120 623 participants aged 35-79 years (mean age 52 [SD 12]; 67 694 [56%] women). At recruitment, 22 670 (43%) men and 9490 (14%) women were current alcohol drinkers, with 15 433 (29%) men and 3054 (5%) women drinking at least weekly; most alcohol consumption was from rum. All-cause mortality was positively and continuously associated with weekly alcohol consumption: each additional 35cl bottle of rum per week (110g of pure alcohol) was associated with ∼10% higher risk of all-cause mortality (RR 1.08 [95%CI 1.05-1.11]). The major causes of excess mortality in weekly drinkers were cancer, vascular disease, and external causes. Non-drinkers had ∼10% higher risk (RR 1.11 [1.09-1.14]) of all-cause mortality than those in the lowest category of weekly alcohol consumption (<1 bottle/week), but this association was almost completely attenuated on exclusion of early follow-up. Interpretation: In this large prospective study in Cuba, weekly alcohol consumption was continuously related to premature mortality. Reverse causality is likely to account for much of the apparent excess risk among non-drinkers. The findings support limits to alcohol consumption that are lower than present recommendations in Cuba. Funding: Medical Research Council, British Heart Foundation, Cancer Research UK, CDC Foundation (with support from Amgen) © 2021 The Authors |
Alcohol; Cuba; Mortality; Prospective study |
antihypertensive agent; adult; age distribution; aged; alcohol consumption; Article; body mass; controlled study; Cuba; diastolic blood pressure; evidence based medicine; female; follow up; health care policy; human; hypertension; ICD-10; ICD-9; major clinical study; male; mortality; mortality rate; premature mortality; prospective study; regression analysis; risk assessment; risk factor; sex difference; systolic blood pressure |
Lancet Publishing Group |
25895370 |
|
|
Article |
Q1 |
1915 |
1435 |
|
|
531 |
Lazarus G., Tjoa K., Iskandar A.W.B., Louisa M., Sagwa E.L., Padayatchi N., Soetikno V. |
57214599425;57222366705;57217632802;41461551400;53464303100;6603387290;36769252100; |
The effect of human immunodeficiency virus infection on adverse events during treatment of drug-resistant tuberculosis: A systematic review and meta-analysis |
2021 |
PLoS ONE |
16 |
3 March |
e0248017 |
|
|
|
|
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85102483457&doi=10.1371%2fjournal.pone.0248017&partnerID=40&md5=e604a5ae346e4c3a4b38a5f906459a26 |
Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Department of Pharmacology and Therapeutics, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Windhoek, Namibia; Nairobi, Kenya; CAPRISA MRC-HIV-TB Pathogenesis and Treatment Research Unit, Durban, South Africa |
Lazarus, G., Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Tjoa, K., Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Iskandar, A.W.B., Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Louisa, M., Department of Pharmacology and Therapeutics, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Sagwa, E.L., Windhoek, Namibia, Nairobi, Kenya; Padayatchi, N., CAPRISA MRC-HIV-TB Pathogenesis and Treatment Research Unit, Durban, South Africa; Soetikno, V., Department of Pharmacology and Therapeutics, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia |
Background Adverse events (AEs) during drug-resistant tuberculosis (DR-TB) treatment, especially with human immunodeficiency virus (HIV) co-infection, remains a major threat to poor DR-TB treatment adherence and outcomes. This meta-analysis aims to investigate the effect of HIV infection on the development of AEs during DR-TB treatment. Methods Eligible studies evaluating the association between HIV seropositivity and risks of AE occurrence in DR-TB patients were included in this systematic review. Interventional and observational studies were assessed for risk of bias using the Risk of Bias in Nonrandomized Studies of Intervention and Newcastle-Ottawa Scale tool, respectively. Random-effects meta-analysis was performed to estimate the pooled risk ratio (RR) along with their 95% confidence intervals (CIs). Results A total of 37 studies involving 8657 patients were included in this systematic review. We discovered that HIV infection independently increased the risk of developing AEs in DR-TB patients by 12% (RR 1.12 [95% CI: 1.02-1.22]; I2 = 0%, p = 0.75). In particular, the risks were more accentuated in the development of hearing loss (RR 1.44 [95% CI: 1.18-1.75]; I2 = 60%), nephrotoxicity (RR 2.45 [95% CI: 1.20-4.98], I2 = 0%), and depression (RR 3.53 [95% CI: 1.38-9.03]; I2 = 0%). Although our findings indicated that the augmented risk was primarily driven by antiretroviral drug usage rather than HIV-related immunosuppression, further studies investigating their independent effects are required to confirm our findings. Conclusion HIV co-infection independently increased the risk of developing AEs during DR-TB treatment. Increased pharmacovigilance through routine assessments of audiological, renal, and mental functions are strongly encouraged to enable prompt diagnosis and treatment in patients experiencing AEs during concomitant DR-TB and HIV treatment. Copyright: © 2021 Lazarus et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
|
antiretrovirus agent; efavirenz; ethionamide; kanamycin; lamivudine; pyrazinamide; tenofovir; tuberculostatic agent; tuberculostatic agent; adverse event; antiretroviral therapy; coinfection; confidence interval; data analysis; data extraction; data quality assessment; depression; drug resistant tuberculosis; hearing impairment; human; Human immunodeficiency virus infection; immune deficiency; meta analysis; nephrotoxicity; Newcastle-Ottawa scale; Review; statistical analysis; systematic review; adverse drug reaction; complication; depression; hearing impairment; Human immunodeficiency virus infection; kidney failure; multidrug resistant tuberculosis; Antitubercular Agents; Depression; Drug-Related Side Effects and Adverse Reactions; Hearing Loss; HIV Infections; Humans; Renal Insufficienc |
Public Library of Science |
19326203 |
|
33662024 |
Review |
Q1 |
990 |
4434 |
|
|
533 |
Harzif A.K., Maidarti M., Ginanjar I., Shadrina A., Meutia A.P. |
57191493435;56320510400;57222277529;57195984988;57203368133; |
Vesicouterine fistula presenting with cyclical haematuria mimicking bladder endometriosis: A case report |
2021 |
International Journal of Surgery Case Reports |
80 |
|
105709 |
|
|
|
1 |
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85102104682&doi=10.1016%2fj.ijscr.2021.105709&partnerID=40&md5=a7cce7444d199f8f94c660f216a8bc66 |
Department of Obstetrics and Gynecology, Faculty of Medicine University of Indonesia Cipto Mangunkusumo Hospital, Jakarta, Indonesia |
Harzif, A.K., Department of Obstetrics and Gynecology, Faculty of Medicine University of Indonesia Cipto Mangunkusumo Hospital, Jakarta, Indonesia; Maidarti, M., Department of Obstetrics and Gynecology, Faculty of Medicine University of Indonesia Cipto Mangunkusumo Hospital, Jakarta, Indonesia; Ginanjar, I., Department of Obstetrics and Gynecology, Faculty of Medicine University of Indonesia Cipto Mangunkusumo Hospital, Jakarta, Indonesia; Shadrina, A., Department of Obstetrics and Gynecology, Faculty of Medicine University of Indonesia Cipto Mangunkusumo Hospital, Jakarta, Indonesia; Meutia, A.P., Department of Obstetrics and Gynecology, Faculty of Medicine University of Indonesia Cipto Mangunkusumo Hospital, Jakarta, Indonesia |
Vesicouterine fistula (VUF) is an abnormal communication between the bladder and uterus, occurring 1–4% of all urogenital fistulas. Diagnosis is still a challenge because symptoms may appear late or fistula may be missed even after repeated examination. A 37-year old woman who has two children born through caesarean section complained of the absence of menstruation for the past three years. At the same time point, she experienced cyclic haematuria and amenorrhea. The diagnosis was made through ultrasonography, cystoscopy and hysteroscopy. She was then managed with laparoscopic bladder fistula repair continued with total laparoscopic hysterectomy. The VUF can present as an undesirable consequence of caesarean section. © 2021 The Authors |
Case report; Cyclic hematuria; Secondary amenorrhea; Vesicocervical fistula |
contrast medium; adult; Article; bladder disease; bladder fistula; bladder injury; bladder neck; bladder trigone; case report; cesarean section; clinical article; contrast enhancement; cystoscopy; cystostomy; endometrial thickness; endometriosis; female; hematuria; human; hysterectomy; hysterosalpingography; hysteroscopy; laparoscopic surgery; postoperative period; premenstrual syndrome; priority journal; reconstructive surgery; secondary amenorrhea; transvaginal echography; urography; uterus disease; vesicouterine fistula; x-ray computed tomography |
Elsevier Ltd |
22102612 |
|
|
Article |
Q3 |
232 |
17549 |
|
|
534 |
Lamontagne F., Agoritsas T., Siemieniuk R., Rochwerg B., Bartoszko J., Askie L., MacDonald H., Amin W., Bausch F.J., Burhan E., Cecconi M., Chanda D., Dat V.Q., Du B., Geduld H., Gee P., Nerina H., Hashimi M., Hunt B.J., Kabra S., Kanda S., Kawano-Dourado L., Kim Y.-J., Kissoon N., Kwizera A., Leo Y.-S., Mahaka I., Manai H., Mino G., Nsutebu E., Pshenichnaya N., Qadir N., Ranganathan S.S., Sabzwari S., Sarin R., Sharland M., Shen Y., Souza J.P., Stegemann M., Ugarte S., Venkatapuram S., Vuyiseka D., Preller J., Brignardello-Petersen R., Kum E., Qasim A., Zeraatkar D., Owen A., Guyatt G., Lytvyn L., Diaz J., Vandvik P.O., Jacobs M. |
15829826700;9734624300;23981410900;24345132600;56940778900;6603045596;57223601603;57221910483;57192706123;36058554600;16505953800;26029327700;56046962100;36131305900;36544760800;57204935223;57222260351;57222257762;55246203600;36488033400;57218352115;45561384900;7410198066;57221100878;35208486000;7004240142;56957092900;57211044922;57222258682;6603293930;6504380233;55622346400;6506124670;35240808700;23006204200;57203106412;16744841200;13205307600;23480876400;25654264800;25937500100;57079260800;55318241800;45161122100;57221470276;57206787520;57190033017;7202052634;8841196600;56600867200;13404130400;6602321455;36848322200; |
A living WHO guideline on drugs to prevent covid-19 |
2021 |
The BMJ |
372 |
|
n526 |
|
|
|
29 |
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85102047389&doi=10.1136%2fbmj.n526&partnerID=40&md5=4b6b72a2cd8535abedd1f2abe649c5ac |
Université de Sherbrooke, Centre de Recherche Due Chu de Sherbrooke, Sherbrooke, QC, Canada; Division of General Internal Medicine, Division of Clinical Epidemiology, University Hospitals of Geneva, Geneva, Switzerland; Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada; Magic Evidence Ecosystem Foundation, Oslo, Norway; Department of Medicine, McMaster University, Hamilton, ON, Canada; World Health Organization, Geneva, Switzerland; The Bmj, London, United Kingdom; Ministry of Health and Population, Cairo, Egypt; Geneva University Hospital, Switzerland; Infection Division, Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Indonesia, Indonesia; Department of Anesthesia and Intensive Care Medicine, Humanitas Clinical and Research Center-IRCCS, Rozzano, Italy; Adult Infectious Disease Centre, University Teaching Hospital, Lusaka, Zambia; Department of Infectious Diseases, Hanoi Medical University, Hanoi, Viet Nam; Peking Union Medical College Hospital, Beijing, China; Division of Emergency Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa; United States; Royal Melbourne Hospital, Melbourne, Australia; Ziauddin University, Karachi, Pakistan; Guy's and St Thomas' Nhs Foundation Trust, London, United Kingdom; All India Institute of Medical Sciences, New Delhi, India; McMaster University (Alumnus), Canada; Pulmonary Division, Heart Institute (InCor)- Hcfmusp, Medical School, University of Sao Paulo, São Paulo, Brazil; Sungkyunkwan University, School of Medicine, Samsung Medical Center, Seoul, South Korea; Department of Paediatrics and Emergency Medicine, University of British Columbia, Vancouver, Canada; Department of Anaesthesia and Critical Care, College of Health Sciences, Makerere University, Kampala, Uganda; National Center for Infectious Diseases, Singapore, Singapore; Pangaea Harare, Zimbabwe; Emergency Medical Services, Faculty of Medicine, Tunis, Tunisia; Alcivar Hospital, Guayaquil, Ecuador; Sheikh Shakhbout Medical City, Abu Dhabi, United Arab Emirates; Central Research Institute of Epidemiology of Rospotrebnadzor, Moscow, Russian Federation; Division of Pulmonary and Critical Care Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, United States; University of Colombo, Colombo, Sri Lanka; Aga Khan University, Karachi, Pakistan; National Institute of Tuberculosis and Respiratory Diseases, New Delhi, India; St. George's University Hospital, London, United Kingdom; Shanghai Public Health Clinical Center, Fudan University, Shanghai, China; University of Sao Paulo, Sao Paulo, Brazil; Charité - Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, Department of Infectious Diseases and Respiratory Medicine, Berlin, Germany; Faculty of Medicine, Andres Bello University, Indisa Clinic, Santiago, Chile; King's College, London, United Kingdom; University of Stellenbosch, South Africa; University of Liverpool, Liverpool, United Kingdom; Department of Health Economics and Health Management, Institute for Health and Society, University of Oslo, Oslo, Norway; Royal Free London Nhs Foundation Trust, London, United Kingdom; Research Institute, Hospital Do Coração (HCor), São Paulo, Brazil |
Lamontagne, F., Université de Sherbrooke, Centre de Recherche Due Chu de Sherbrooke, Sherbrooke, QC, Canada; Agoritsas, T., Division of General Internal Medicine, Division of Clinical Epidemiology, University Hospitals of Geneva, Geneva, Switzerland, Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada, Magic Evidence Ecosystem Foundation, Oslo, Norway; Siemieniuk, R., Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada, Department of Medicine, McMaster University, Hamilton, ON, Canada; Rochwerg, B., Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada, Department of Medicine, McMaster University, Hamilton, ON, Canada; Bartoszko, J., Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada; Askie, L., World Health Organization, Geneva, Switzerland; MacDonald, H., The Bmj, London, United Kingdom; Amin, W., Ministry of Health and Population, Cairo, Egypt; Bausch, F.J., Geneva University Hospital, Switzerland; Burhan, E., Infection Division, Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Indonesia, Indonesia; Cecconi, M., Department of Anesthesia and Intensive Care Medicine, Humanitas Clinical and Research Center-IRCCS, Rozzano, Italy; Chanda, D., Adult Infectious Disease Centre, University Teaching Hospital, Lusaka, Zambia; Dat, V.Q., Department of Infectious Diseases, Hanoi Medical University, Hanoi, Viet Nam; Du, B., Peking Union Medical College Hospital, Beijing, China; Geduld, H., Division of Emergency Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa; Gee, P., United States; Nerina, H., Royal Melbourne Hospital, Melbourne, Australia; Hashimi, M., Ziauddin University, Karachi, Pakistan; Hunt, B.J., Guy's and St Thomas' Nhs Foundation Trust, London, United Kingdom; Kabra, S., All India Institute of Medical Sciences, New Delhi, India; Kanda, S., McMaster University (Alumnus), Canada; Kawano-Dourado, L., Pulmonary Division, Heart Institute (InCor)- Hcfmusp, Medical School, University of Sao Paulo, São Paulo, Brazil, Research Institute, Hospital Do Coração (HCor), São Paulo, Brazil; Kim, Y.-J., Sungkyunkwan University, School of Medicine, Samsung Medical Center, Seoul, South Korea; Kissoon, N., Department of Paediatrics and Emergency Medicine, University of British Columbia, Vancouver, Canada; Kwizera, A., Department of Anaesthesia and Critical Care, College of Health Sciences, Makerere University, Kampala, Uganda; Leo, Y.-S., National Center for Infectious Diseases, Singapore, Singapore; Mahaka, I., Pangaea Harare, Zimbabwe; Manai, H., Emergency Medical Services, Faculty of Medicine, Tunis, Tunisia; Mino, G., Alcivar Hospital, Guayaquil, Ecuador; Nsutebu, E., Sheikh Shakhbout Medical City, Abu Dhabi, United Arab Emirates; Pshenichnaya, N., Central Research Institute of Epidemiology of Rospotrebnadzor, Moscow, Russian Federation; Qadir, N., Division of Pulmonary and Critical Care Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, United States; Ranganathan, S.S., University of Colombo, Colombo, Sri Lanka; Sabzwari, S., Aga Khan University, Karachi, Pakistan; Sarin, R., National Institute of Tuberculosis and Respiratory Diseases, New Delhi, India; Sharland, M., St. George's University Hospital, London, United Kingdom; Shen, Y., Shanghai Public Health Clinical Center, Fudan University, Shanghai, China; Souza, J.P., University of Sao Paulo, Sao Paulo, Brazil; Stegemann, M., Charité - Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, Department of Infectious Diseases and Respiratory Medicine, Berlin, Germany; Ugarte, S., Faculty of Medicine, Andres Bello University, Indisa Clinic, Santiago, Chile; Venkatapuram, S., King's College, London, United Kingdom; Vuyiseka, D., University of Stellenbosch, South Africa; Preller, J., World Health Organization, Geneva, Switzerland; Brignardello-Petersen, R., Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada; Kum, E., Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada; Qasim, A., Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada; Zeraatkar, D., Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada; Owen, A., University of Liverpool, Liverpool, United Kingdom; Guyatt, G., Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada, Department of Medicine, McMaster University, Hamilton, ON, Canada; Lytvyn, L., Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada; Diaz, J., World Health Organization, Geneva, Switzerland; Vandvik, P.O., Magic Evidence Ecosystem Foundation, Oslo, Norway, Department of Health Economics and Health Management, Institute for Health and Society, University of Oslo, Oslo, Norway; Jacobs, M., Royal Free London Nhs Foundation Trust, London, United Kingdom |
Clinical question What is the role of drugs in preventing covid-19? Why does this matter? There is widespread interest in whether drug interventions can be used for the prevention of covid-19, but there is uncertainty about which drugs, if any, are effective. The first version of this living guideline focuses on the evidence for hydroxychloroquine. Subsequent updates will cover other drugs being investigated for their role in the prevention of covid-19. Recommendation The guideline development panel made a strong recommendation against the use of hydroxychloroquine for individuals who do not have covid-19 (high certainty). How this guideline was created This living guideline is from the World Health Organization (WHO) and provides up to date covid-19 guidance to inform policy and practice worldwide. Magic Evidence Ecosystem Foundation (MAGIC) provided methodological support. A living systematic review with network analysis informed the recommendations. An international guideline development panel of content experts, clinicians, patients, an ethicist and methodologists produced recommendations following standards for trustworthy guideline development using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. Understanding the new recommendation The linked systematic review and network meta-analysis (6 trials and 6059 participants) found that hydroxychloroquine had a small or no effect on mortality and admission to hospital (high certainty evidence). There was a small or no effect on laboratory confirmed SARS-CoV-2 infection (moderate certainty evidence) but probably increased adverse events leading to discontinuation (moderate certainty evidence). The panel judged that almost all people would not consider this drug worthwhile. In addition, the panel decided that contextual factors such as resources, feasibility, acceptability, and equity for countries and healthcare systems were unlikely to alter the recommendation. The panel considers that this drug is no longer a research priority and that resources should rather be oriented to evaluate other more promising drugs to prevent covid-19. Updates This is a living guideline. New recommendations will be published in this article and signposted by update notices to this guideline. Readers note This is the first version of the living guideline for drugs to prevent covid-19. It complements the WHO living guideline on drugs to treat covid-19. When citing this article, please consider adding the update number and date of access for clarity. © Published by the BMJ Publishing Group Limited. |
|
hydroxychloroquine; hydroxychloroquine; immunologic factor; coronavirus disease 2019; drug use; health care policy; high risk patient; human; immune response; infection prevention; nonhuman; practice guideline; Review; Severe acute respiratory syndrome coronavirus 2; World Health Organization; chemoprophylaxis; clinical decision making; drug effect; epidemiology; practice guideline; prevention and control; procedures; risk assessment; uncertainty; Chemoprevention; Clinical Decision-Making; COVID-19; Humans; Hydroxychloroquine; Immunologic Factors; Risk Assessment; SARS-CoV-2; Uncertainty; World Health Organization |
BMJ Publishing Group |
09598146 |
|
33649077 |
Review |
Q1 |
1831 |
1579 |
|
|